Achilles Therapeutics Ltd. announced it has closed a £100 million Series B financing led by incoming U.S. investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, In association with the financing, Achilles has added two leading life science executives to the Board: Dr. Derek DiRocco, Principal of RA Capital Management and Dr. Rogier Rooswinkel, Partner at Forbion.